These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 22422826)

  • 1. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
    Eghtedar A; Verstovsek S; Estrov Z; Burger J; Cortes J; Bivins C; Faderl S; Ferrajoli A; Borthakur G; George S; Scherle PA; Newton RC; Kantarjian HM; Ravandi F
    Blood; 2012 May; 119(20):4614-8. PubMed ID: 22422826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
    Moskowitz AJ; Ghione P; Jacobsen E; Ruan J; Schatz JH; Noor S; Myskowski P; Vardhana S; Ganesan N; Hancock H; Davey T; Perez L; Ryu S; Santarosa A; Dowd J; Obadi O; Pomerantz L; Yi N; Sohail S; Galasso N; Neuman R; Liotta B; Blouin W; Baik J; Geyer MB; Noy A; Straus D; Kumar P; Dogan A; Hollmann T; Drill E; Rademaker J; Schoder H; Inghirami G; Weinstock DM; Horwitz SM
    Blood; 2021 Dec; 138(26):2828-2837. PubMed ID: 34653242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.
    Dao KT; Gotlib J; Deininger MMN; Oh ST; Cortes JE; Collins RH; Winton EF; Parker DR; Lee H; Reister A; Schultz ; Savage S; Stevens ; Brockett C; Subbiah N; Press RD; Raess PW; Cascio M; Dunlap J; Chen Y; Degnin C; Maxson JE; Tognon CE; Macey T; Druker BJ; Tyner JW
    J Clin Oncol; 2020 Apr; 38(10):1006-1018. PubMed ID: 31880950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia.
    Altman JK; Perl AE; Hill JE; Rosales M; Bahceci E; Levis MJ
    Cancer Med; 2021 Feb; 10(3):797-805. PubMed ID: 33340276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burkitt leukemia with precursor B-cell features that developed after ruxolitinib treatment in a patient with hydroxyurea-refractory JAK2
    Fukutsuka K; Iioka F; Maekawa F; Nakagawa M; Kishimori C; Hayashida M; Tagawa S; Akasaka T; Honjo G; Ohno H
    J Clin Exp Hematop; 2021 Jun; 61(2):114-119. PubMed ID: 33994432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
    Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
    BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase.
    Mascarenhas JO; Rampal RK; Kosiorek HE; Bhave R; Hexner E; Wang ES; Gerds A; Abboud CN; Kremyanskaya M; Berenzon D; Odenike O; Farnoud N; Krishnan A; Weinberg RS; McGovern E; Salama ME; Najfeld V; Medina-Martinez JS; Arango Ossa JE; Levine MF; Zhou Y; Sandy L; Heaney ML; Levine RL; Mesa RA; Dueck AC; Hoffman R
    Blood Adv; 2020 Oct; 4(20):5246-5256. PubMed ID: 33104796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells.
    Fiskus W; Manshouri T; Birdwell C; Mill CP; Masarova L; Bose P; Kadia TM; Daver N; DiNardo CD; Borthakur G; Khoury JD; Verstovsek S; Bhalla KN
    Blood Cancer J; 2022 Jan; 12(1):23. PubMed ID: 35102145
    [No Abstract]   [Full Text] [Related]  

  • 10. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells.
    Fiskus W; Mill CP; Nabet B; Perera D; Birdwell C; Manshouri T; Lara B; Kadia TM; DiNardo C; Takahashi K; Daver N; Bose P; Masarova L; Pemmaraju N; Kornblau S; Borthakur G; Montalban-Bravo G; Manero GG; Sharma S; Stubbs M; Su X; Green MR; Coarfa C; Verstovsek S; Khoury JD; Vakoc CR; Bhalla KN
    Blood Cancer J; 2021 May; 11(5):98. PubMed ID: 34016956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib for refractory large granular lymphocyte leukemia.
    Moignet A; Pastoret C; Cartron G; Coppo P; Lamy T
    Am J Hematol; 2021 Oct; 96(10):E368-E370. PubMed ID: 34133042
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of ruxolitinib on infection in patients with myeloproliferative neoplasm: a meta-analysis.
    Luo Q; Xiao Z; Peng L
    Hematology; 2021 Dec; 26(1):663-669. PubMed ID: 34493151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proof of concept of triple COMBI therapy to prohibit MPN progression to AML.
    Hasselbalch HC; Skov V; Kjaer L; Larsen MK
    Br J Haematol; 2024 Jan; 204(1):16-18. PubMed ID: 37957927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of PCM1-JAK2-positive myeloproliferative neoplasm with eosinophilia using ruxolitinib: a case report].
    Song Y; Zhang YR; Han Y; Wang Y; Li YQ; Chai Y; Zeng PY; Yue LL; Wu CY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):690. PubMed ID: 34547879
    [No Abstract]   [Full Text] [Related]  

  • 15. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
    Al Barashdi MAS; Ali A; McMullin MF; Mills K
    Ann Hematol; 2024 Jan; 103(1):73-88. PubMed ID: 37917373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid-refractory/dependent acute, gastrointestinal graft-versus-host disease: A case series.
    Biliński J; Jasiński M; Tomaszewska A; Lis K; Kacprzyk P; Chmielewska L; Karakulska-Prystupiuk E; Mullish BH; Basak GW
    Am J Hematol; 2021 Dec; 96(12):E461-E463. PubMed ID: 34587331
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 in a patient with idiopathic pulmonary fibrosis successfully treated with Ruxolitinib.
    Caradec E; Mouren D; Zrounba M; Azoulay LD; Blandin C; Ivanoff S; Levy V; Brillet PY; Nunes H; Uzunhan Y
    Respir Med Res; 2021 May; 79():100799. PubMed ID: 33242734
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
    Systchenko T; Chomel JC; Gallego-Hernanz P; Moya N; Desmier D; Maillard N; Bobin A; Vonfeld M; Gardeney H; Cayssials E E; Torregrosa J
    Br J Haematol; 2023 Jul; 202(2):284-288. PubMed ID: 37183377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib Controls Lymphoproliferation and Diabetes in a STAT3-GOF Patient.
    Wegehaupt O; Muckenhaupt T; Johnson MB; Schwab KO; Speckmann C
    J Clin Immunol; 2020 Nov; 40(8):1207-1210. PubMed ID: 32944850
    [No Abstract]   [Full Text] [Related]  

  • 20. Low-dose methotrexate in myeloproliferative neoplasm models.
    Chinnaiya K; Lawson MA; Thomas S; Haider MT; Down J; Chantry AD; Hughes D; Green A; Sayers JR; Snowden JA; Zeidler MP
    Haematologica; 2017 Sep; 102(9):e336-e339. PubMed ID: 28550185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.